Evidence map›Paper›PMID 42276425›Full record

ArticleInternational journal of radiation oncology, biology, physics2026

Characteristics of Crowdfunding Campaigns for Proton Therapy.

Edson A Damian-Jacobo, Xiaohan Chi, Ethan B Ludmir, Fumiko Chino, Ruitao Lin, Eugene J Koay, Anna Lee, Susan Y Wu

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edson A Damian-JacoboDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xiaohan ChiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ethan B LudmirDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Fumiko ChinoDepartment of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ruitao LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eugene J KoayDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Anna LeeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Susan Y WuDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: Sywu1@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeAdvanced radiation oncology techniques such as proton therapy allow more precise treatment delivery, with improved toxicity profiles; however, insurance coverage is variable. In addition to direct treatment-related costs, radiation treatment contributes to the financial toxicity of cancer treatment through indirect costs such as lodging, lost wages, and travel. GoFundMe is a leading crowdfunding platform, with one-third of donations supporting health care costs. We sought to identify characteristics of proton crowdfunding campaigns that met their fundraising goal. METHODS AND MATERIALS: GoFundMe was queried for fundraisers with keywords such as proton therapy, proton radiation from February 2024 to March 2025. Details, such as treatment site, patient demographic characteristics, and use of funds, were abstracted from the campaign website. Campaigns were considered fulfilled if they met 100% of the goal.

resultsSix hundred ninety-nine campaigns were included in this analysis, with a median fundraising goal of $20,000 (IQR, $10,000-$40,000) and a median amount raised of $7790 (IQR, $3470-$15,418). The most common malignancies noted in campaigns were of the central nervous system (45%, 313/699), followed by head and neck (16%, 108/699). Twenty-two percent of campaigns (150/699) noted that proton therapy was not covered by insurance, which was associated with a greater likelihood of being fully funded (P = .023). Campaigns with links to additional information (hospital where proton therapy would be delivered, and external sites with information about the malignancy being treated) were also more likely to be fully funded (P = .021). On univariate analysis, pediatric beneficiaries and lack of insurance coverage for proton therapy were associated with funds raised (P ≤ .001 for both).

conclusionsCrowdfunding may be a financial safety net for patients with cancer. The success of crowdfunding campaigns may be influenced by patient demographics, insurance coverage, and donor engagement.

Indexed as

CrowdsourcingFund RaisingHealth Care CostsNeoplasmsProton TherapyHumansInsurance Coverage

Identifiers

PMID42276425
PMCPMC13644400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.